• Explore /
  • Poster
  • / Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Updated results from ZUMA-3, a phase 1/2 study of KTE-C19 chimeric antigen receptor (CAR) T cell therapy, in adults with high-burden relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Abstract Poster

Authors

null

Bijal D. Shah

H. Lee Moffitt Cancer Canter and Research Institute, Tampa, FL

Bijal D. Shah , William G. Wierda , Gary J. Schiller , Michael Russell Bishop , Januario E. Castro , Marianna Sabatino , Adrian Bot , Armen Mardiros , John Rossi , Yizhou Jiang , Lynn Navale , Shanna Stout , Jeff Aycock , Jeffrey S. Wiezorek , Rajul K. Jain

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT02614066

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3024)

DOI

10.1200/JCO.2017.35.15_suppl.3024

Abstract #

3024

Poster Bd #

119

Abstract Disclosures

Similar Posters

First Author: Paolo Strati

First Author: Sattva Swarup Neelapu

First Author: Olalekan O. Oluwole

First Author: Gregory P. Botta